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Edited by Peter Tontonoz and Laszlo NagyAbstract Forkhead transcription factors FoxOs are conserved
beyond species and regulated by insulin signaling pathway. Fox-
Os have diverse functions on diﬀerentiation, proliferation and
cell survival. In calorie restriction (CR) or starvation, FoxOs
are in nucleus, active transcriptionally, and increase hepatic glu-
cose production, decrease insulin secretion, increase food intake
and cause degradation of skeletal muscle for supplying substrates
for glucose production. However, even in insulin resistance due to
excessive calorie intake, FoxOs are active and causes type 2 dia-
betes and hyperlipidemia. The understanding of molecular mech-
anism how FoxOs aﬀect glucose or lipid metabolism will shed
light on the novel therapy of type 2 diabetes and the metabolic
syndrome.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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In nematode Caenorhabditis elegans (C. elegans), in response
to increased levels of a secreted pheromone as well as food
deprivation during early larval stage (L1), worms can enter
an alternative developmental mode and form dauer larvae
[1,2]. DAF-2 (a homolog of the mammalian insulin receptor)
pathway regulates a state of dauer. Analyses of several mutant
C. elegans identiﬁed several genes, which includes age-1 (a
homolog of the catalytic subunit of mammalian phosphatidyl-
inositol 3-OH kinase) and akt. Loss-of-function mutants of
these genes showed extended lifespan and/or constitutive dauer
formation [3]. Daf-16 was initially isolated as a gene that
caused a dauer defective phenotype when mutated and found
that it encodes a forkhead/HNF3-related transcription factor
[3,4]. The closest human orthologues are FKHR (FOXO1),
FKHR-L1 (FOXO3A), and AFX (FOXO4) [5]. It was specu-
lated that they might act downstream of insulin signaling
and be deregulated in diabetes.
Initially, a subset of FOXO genes has been identiﬁed with
disorders like rhabdomyosarcomas and tumorigenesis. A form
of rhabdomyosarcoma is caused by a translocation between*Corresponding author. Fax: +81 78 382 5379.
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doi:10.1016/j.febslet.2007.11.025chromosome 2 or chromosome 1 and chromosome 13 [t
(1, 13) or t (2,13)], which leads to fusion of the PAX7 or
PAX3 gene with FOXO1. FOXO3A and FOXO4 are fusion
partners of MLL in acute myeloid leukemias (AMLs) associ-
ated with t (6; 11)(q21; q23) or t (X; 11)(q13; q23), respectively
[6]. The winged helix/forkhead class of transcription factors is
characterized by a 100-amino acid, monomeric DNA-binding
domain. The DNA-binding domain folds into a variant of
the helix–turn–helix motif and is made up of three a helices
and two characteristic large loops, or wings. Therefore, the
DNA-binding motif has been named the winged helix DNA-
binding domain [7]. Until the present time, over 100 members
of this gene family have been identiﬁed. In 2000, in order to
standardize the nomenclature for these proteins, Fox (Fork-
head box) was adopted as the uniﬁed symbol for all chordate
winged helix/forkhead transcription factors [8]. Since 1999,
many FoxO-target genes and -functions were identiﬁed. These
studies have been reviewed extensively elsewhere [5,6].
In the present review, we will summarize metabolic eﬀects of
FoxOs in insulin responsive tissues and discuss how FoxOs
regulate glucose and lipid metabolism.2. Regulation of FoxOs’ activity
2.1. Regulation of phosphorylation and subcellular localization
of FoxOs by PI-3kinase-dependent way
After insulin, IGF-1 or other growth factors bind to their
tyrosine kinase receptors and activate phosphoinositide kinase
(PI3K), several serine/threonine kinases, which include the Akt
family protein kinases and the related serum and glucocorti-
coid inducible kinase (SGK) are activated [9]. FoxOs have
three consensus phosphorylation sites (RXRXXS/T) of Akt
(threonine 24, serine 253 and serine 316 in murine FoxO1)
although DAF-16 in C. elegans has four consensus Akt phos-
phorylation sites [10–15]. Serine 253 acts as a gatekeeper site
for phosphorylation of FoxO1 and phosphorylation of Serine
253 is needed for subsequent phosphorylation of Threonine 24
and Serine 316 [12]. Not only Akt phosphorylates these sites
but also, in some cell lines, another kinase, SGK, phosphory-
lates FoxOs. Each kinase has preferential sites for phosphory-
lation of FoxOs. Akt phosphorylates Serine 253 and SGK
phosphorylates Serine 316 preferentially. Threonine 24 is phos-
phorylated by both kinases [10] (Fig. 1).
Phosphorylation of three Akt/SGK phosphorylation sites
causes changes of subcellular localization of FoxOs [10,15].
In inactivated state of Akt/SGK, FoxOs are in nucleus andblished by Elsevier B.V. All rights reserved.
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Fig. 1. Phosphorylation and regulation of nuclear export of FoxO1. Insulin or growth factor binds to IR or other tyrosine kinase receptor and leads
to activation of PI3K pathway. Akt/SGK phosphorylates Threonine 24, Serine 253, and Serine 316 of FoxO1. The chaperone protein, 14-3-3, binds
to phosphorylated Threonine 24 and Serine 253 and promotes the nuclear export of FoxO1. The 14-3-3 binding to NLS also prevents nuclear import
of FoxO1 and these events leads to exposure of NES and interaction with Exportin/Crm1. Phosphorylation of Serine 319 and 322 by CK1 accelerates
FoxO1 relocalization by interaction with Exportin/Crm1.
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genes. After stimulation with several growth factors, Akt/
SGK is activated and phosphorylates FoxOs and causes the
export of FoxOs to the cytoplasm. Several mechanisms about
shuttling of FoxOs between nucleus and cytoplasma have been
described. FoxOs have a nuclear export sequence (NES) in the
conserved C-terminal region [15]. Furthermore, a chaperone
molecules, 14-3-3 protein, binds to phosphorylated FoxOs
[10,16]. 14-3-3 binding may decrease the ability of FoxOs to
bind DNA, releasing FoxOs from DNA [17]. 14-3-3 binding
to FoxOs may promote the nuclear export of FoxOs by induc-
ing a conformational change in FoxO molecules that would ex-
pose the NES and allow interaction with Exportin/Crm1 [16].
14-3-3 binding to FoxOs may also prevent the nuclear import
of FoxOs by masking FoxO nuclear localization signal (NLS)
[18,19] (Fig. 1).
FoxO6, which is another member of FoxOs, has been iden-
tiﬁed recently. FoxO6 has only two Akt/SGK phosphorylation
sites (Threonine 26 and Serine 184 in mouse FoxO6) and stays
in nucleus mostly. However, phosphorylation of these two sites
decreases transcriptional activity of FoxO6 [20].
However, only nuclear localization may not give FoxOs full
transcriptional activity because studies in C. elegans demon-
strated that the DAF-2 pathway still inhibited dauer formation
and lifespan extension even when the consensus Akt sites on
DAF-16a are not phosphorylated [21]. Further analyses of reg-
ulation of FoxOs’ activities might be needed.
2.2. Regulation of FoxOs by other signaling pathways
It has been reported that other kinases phosphorylate sev-
eral diﬀerent sites in response to insulin and growth factors.
Casein kinase 1 (CK1) phosphorylates Serine 319 (in mouse
FoxO1) and Serine 322 in FoxO1 [22] and the dual tyrosinephosphorylated regulated kinase 1 (DYRK1) phosphorylates
Serine 329 [23]. Phosphorylation of Serine 319 and 322 may
also contribute to acceleration of FoxO relocalization to
cytoplasm by increasing the interaction between FoxOs and
the export machinery (Ran and Exportin/Crm1) [22]. Phos-
phorylation of Serine 329 by DYRK1 also accelerates nuclear
export and inhibition of FoxOs’ transcriptional activity [23].
The c-Jun N-terminal kinase (JNK) positively regulates Fox-
Os activity in C. elegans and Drosophila. Activation of JNK
pathway extends life span of both species [24,25]. In C. elegans,
JNK-1 phosphorylates DAF-16. The phosphorylation was ob-
served only with the N-terminal (amino acids 83–307) frag-
ment of DAF-16. Furthermore, it has been demonstrated
that JNK-1 directly interacts with, phosphorylates, enhances
nuclear localization of DAF-16, and induces its target gene
expression [24]. Indeed, low levels of oxidative stress generated
by treatment with H2O2 activates the small GTPase Ral and
induce a JNK-dependent phosphorylation of Threonine 447
and Threonine451, nuclear translocation, and transcriptional
activation of FOXO4 [26].
One of null-mutations in C. elegans, bar-1, which is homolog
of the b-catenin in mammalian, was found as defective mutant
of starvation-induced dauer development [27]. b-catenin is a
multifunctional protein that mediates Wnt signaling by bind-
ing to members of the T-cell factor (TCF) family of transcrip-
tion factors [28,29]. BAR-1 may increase dauer formation and
life span by increasing DAF-16 activity. The physical interac-
tion between FoxOs and b-catenin is conserved. b-catenin en-
hances FoxOs’ transcriptional activity. Insulin stimulation
causes nuclear export of FoxOs and inhibits them. At that
time, b-catenin induces cell proliferation through activation
of TCFs. In contrast, oxidative stress induces nuclear localiza-
tion of FoxOs and b-catenin activates FoxOs’ transcriptional
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that both Wnt signaling pathway and FoxO1 have been shown
to inhibit adipocyte diﬀerentiation suggest a speculative
hypothesis that these two signaling pathway may converge
on promoter regions of their target genes during adipocyte dif-
ferentiation [31–33].Table 1
Phenotypes of FoxOs knockout mice
Knockout mice Phenotypes References
FoxO1/ Embryonic lethal (embryonic day 10.5)
Defects of normal vascular
development in embryo and yolk sac
Lack of aortic arch vessels
[62,63]
FoxO3a/ Viable
Abnormal ovarian follicular
development
Hematological abnormalities
Pituitary adenoma/female,
ovarian stromal tumor
[62,64,65]
FoxO4/ Viable
Impaired neointima formation
Lung adenoma/adenocarcinoma
Pituitary adenoma/female
[62,65]
Mx-Cre+,
FoxO1/3/4L/L
Lymphoblastic thymic lymphoma
Hemangioma
[65,66]2.3. Regulation of FoxOs by CBP/p300-mediated acetylation
and Sirt1-mediated deacetylation
Calorie restriction (CR) was ﬁrst described as a reduction in
food intake in laboratory rodents of between 20% and 40% of
ad libitum levels that would extend their life span by up to 50%
[35]. The eﬀects of CR are beginning with an acute phase upon
imposition of the diet followed by an adaptive period of several
weeks to reach a stable, altered physiological state. A lower
body temperature, lower blood glucose and insulin levels,
and reduced body fat and weight characterize this altered state
[34]. CR regulates Sirt1 expression level and activity. Sirt1 is
one of the seven mammalian Sir2 ortholog, which is a nicotin-
amide adenine dinucleotide (NAD)-dependent histone deace-
tylase [35,36]. Mutant strains of C. elegans with extra copies
of Sir2.1 have increased longevity and Daf16 is epistatic to
Sir2.1 gain-of-function [37]. Sirt1 has several roles in mamma-
lian physiology. In white adipose tissue, Sirt1 was shown to
inhibit adipogenesis in precursor cells and reduce fat storage
in diﬀerentiated cells through inhibition of Ppar c by Sirt dock-
ing with its negative cofactors NcoR and SMRT [38]. In pan-
creatic b-cell, Sirt1 is a positive regulator of insulin secretion.
Lowering Sirt1 in the insulinoma cells activated transcription
of the uncoupling protein 2 gene (Ucp-2), which encodes a mito-
chondrial membrane protein that might uncouple ATP synthe-
sis from respiration. Sirt1 suppresses Ucp-2 expression in
pancreatic b-cells and increases the eﬃciency of ATP synthesis
in response to glucose and ﬁnally positively regulates insulin
secretion [39,40]. Sirt1 was also demonstrated to protect b-cells
against oxidative stress in a mechanism proposed to involve
deacetylation of FoxO1 [41]. Furthermore, Sirt1 is also in-
volved in hepatic gluconeogenesis. Sirt1 binds to and deacety-
lates Pparc coactivator Pgc-1a and FoxO1 and activates them,
resulting in an increase in glucose production [42,43].
FoxOs bind to the transcriptional coactivator CBP (CREB-
binding protein) and to p300, thus providing a connection be-
tween these transcriptional regulators and the basal transcrip-
tional machinery [44–46]. CBP, p300, and PCAF directly
acetylate FoxOs at several conserved lysine residues [47,47,
48]. It has been reported that the acetylation of FoxOs by
CBP suppresses FoxOs’ transcriptional activity [49] and inhib-
its FoxO’s binding to DNA [50]. Although the eﬀects of
deacetylation of FoxOs by Sirt1 vary depending on FoxO-
target genes, Sirt1 has been reported to enhance FoxO’s tran-
scriptional activity on their target genes [47,49,46]. As a whole,
Sirt1 showed that it deacetylates FoxOs and increases the
stress resistance of cells by inhibiting apoptosis and increasing
stress resistance [5]. Other than Lysine residues in FoxOs can
regulate these events. FoxOs have the conserved LXXLL motif
in their C-terminal region. The LXXLL motif of FoxO1 ap-
pears to be important for its binding to Sirt1. Although it
has not been elucidated completely how the LXXLL motif
of FoxO1 mediates the binding to Sirt, the disruption of the
LXXLL motif of FoxO1 inhibits transcriptional activity of
FoxO1 and enhance acetylation of FoxO1 in liver [51].2.4. Ubiquitination and degradation of FoxOs
Another regulation of FoxOs’ activity is the ubiquitination-
mediated degradation of FoxOs in the 26S proteasome.
Matsuzaki et al. has reported that insulin decreased FoxO1
protein levels due to ubiquitination and degradation in the
26S proteasome in the PI3-kinase-dependent manner in
HepG2 cells [52]. Furthermore, Aoki et al. demonstrated that
FoxO1 expression levels were decreased in chicken embryo
ﬁbroblast (CEF) transformed by PI3-kinase and Akt and sug-
gested that phosphorylation-mediated degradation of FoxO1
may play a role in oncogenic transformation by PI3-kinase
and Akt [53].
Many tumor suppressors can be degraded by the ubiquitin
pathway in human cancer. P27KIP1, p130 and p57KIP2 have
been shown to be targeted by the F-box motif in Skp2, an
oncogenic subunit of the Skp1/Cul1/F-box protein ubiquitin
complex, for degradation [54–57]. Skp2 interacts with, ubiqui-
tinates, and promotes the degradation of FOXO1 with Akt-
speciﬁc phosphorylation of Serine 256 [58]. Therefore, Skp2
suppresses tumor-suppressor eﬀects of FoxO1. Furthermore,
Skp2 is also involved in regulation of glucose metabolism,
which includes the regulation of number of pancreatic b-cell,
insulin secretion and adipocyte proliferation during the devel-
opment of obesity [59]. Therefore, ubiquitination and degrada-
tion of FoxO1 by Skp2 may contribute to the onset of insulin
resistance and type 2 diabetes.3. Knockout mice of FoxOs
In order to elucidate physiological roles of each FoxO
in vivo, we have to see phenotypes of each FoxO-knockout
mouse (Table 1). However, we have to mind whether each
FoxO has the same physiological roles or not, whether each
FoxO can compensate another FoxO or not.
3.1. FoxO1 knockout mice
FoxO1-knockout embryos died on embryonic day 10.5 as a
consequence of incomplete vascular development. At E9.5,
FoxO1/ yolk sacs lacked well-developed blood vessels.
The primary defect in FoxO1/ embryos and yolk sacs ap-
pears to be a disruption of normal vascular formation. Indeed,
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ture. FoxO1 has a crucial role in vascular formation [60]. Fur-
thermore, another group demonstrated that FoxO1/ had
defects in the branchial arches and severe cardiac failure due
to the lack of aortic arch vessels and suggested that FoxO1
is indispensable for ‘‘vasculogenesis’’ [61]. FoxO1 is involved
in the later stages of branchial arch formation from precursor
cells or, alternatively, in the migration or survival of a re-
stricted population of neural crest cells contributing to the for-
mation of the ﬁrst and second branchial arches at a speciﬁc
stage.3.2. FoxO3 knockout mice
FoxO3a/ mice are viable and have hematological abnor-
malities (a mild compensated anemia with associated reticulo-
cytosis) and a decreased rate of glucose uptake. Furthermore,
FoxO3a/ female mice have an age-dependent reduced fertil-
ity due to abnormal ovarian follicular development. These
mice showed early and widespread initiation of follicular
growth and subsequently early atretic change by 9.5 weeks
and noticeable absence of growing follicles [62,60]. These data
suggest that FoxO3a may have a suppressive eﬀect on initia-
tion of follicular growth by aﬀecting the mechanism intrinsic
to the ovary. Furthermore, FoxO3a/ mice showed in-
creased occurrences of ovarian stromal tumor and female pitu-
itary adenoma [63].3.3. FoxO4 knockout mice
FoxO4/mice are also viable and grossly indistinguishable
from their littermate controls. Histological analyses of
FoxO4/ mice did not identify any consistent abnormalities
[60]. However, very recently, it has been reported that
FoxO4/ mice showed increased occurrences of lung ade-
noma/adenocarcinoma and female pituitary adenoma [63].
These increased occurrences of pituitary adenoma in both fe-
male FoxO3a/ and FoxO4/ mice suggest to us that Fox-
Os might have some important physiological roles in pituitary.
Indeed, FoxO1 is expressed abundantly in anterior pituitary
lobe (Fig. 2).Fig. 2. FoxO1 is expressed in mouse pituitary lobes. Immunohisto-
chemistry with anti-FOXO1 antibody (green) (ab12161, abcam) and
DAPI (blue) demonstrates that FoxO1 is expressed mainly in anterior
lobe of mouse pituitary and FoxO1 is localized in cytosol. AL, anterior
lobe; IL, intermediate lobe; PL, posterior lobe.3.4. Mx-Cre+; FoxO1/3/4L/L
From several studies using cell lines, FoxO proteins are in-
volved in apoptosis or cell cycle arrest. Therefore, phenotypes
of FoxO3a/ or FoxO4/, the lack of an overt tumor-
prone phenotype, were unanticipated. These studies suggested
the possibility of the physical and functional relatedness and
overlapping expression patterns of the FoxOs or of a relatively
minor role in cancer suppression and vascular biology of Fox-
Os. Paik et al. generated the inducible, widespread somatic
FoxO deleted adult mice, Mx-Cre+; FoxO1/3/4L/L. These mice
developed aggressive CD4+CD8+ lymphoblastic thymic lym-
phomas, an age-progressive hamartomous phenotype in the
endothelial cell lineage with widespread hemangiomas [63].
These extensive studies suggest that tumor formation needs
inactivation of all three FoxOs due to extensive functional
redundancy and that FoxO1 is the most physiologically impor-
tant regulator of endothelial stability, which is consistent with
FoxO1/ mice. Furthermore, the ﬁndings that Mx-Cre+;
FoxO1/3/4L/L showed abnormalities of the hematopoietic sys-
tem, which were not observed in single or double knockout
mutants of FoxOs, suggest the functional redundancy in hema-
topoietic system and a critical role for FoxOs in this system
[64].4. Metabolic eﬀects of FoxOs in insulin-responsive tissues
For a decade, the biology of FoxOs provides a glimpse into
the complex relationship among cellular proliferation, trans-
formation, and metabolism. The researches on metabolism
lead to FoxO1 as the long-sought insulin-regulated transcrip-
tion factor responsible for insulin action on gene expression
[5]. The identiﬁcation of DAF-16 as a negative regulator of
DAF-2 signaling pathway in C. elegans reminded us FoxOs
as antagonistic eﬀectors in insulin actions. At the present time,
various kinds of target genes of FoxOs have been identiﬁed in
insulin-responsive tissues, which include liver, pancreatic b-
cell, fat, skeletal muscle, hypothalamus, and endothelial cells.
In this paragraph, we will focus on metabolic eﬀects of FoxOs
in these insulin-responsive tissues or cells and discuss them
(Fig. 3).4.1. Liver
The hepatic metabolic eﬀects of FoxOs in liver have been
diverged into mainly two categories, gluconeogenesis and
triglyceride metabolism. In mammalians, at CR or food-depri-
vation state, hepatic glucose production is increased and glu-
cose is supplied to brain where glucose is an only source of
energy. Genes that are involved in gluconeogenesis, which
include glucose 6-phosphatase (G6pc) and phosphoenolpyruvate
carboxykinase (Pck1), are upregulated at fasting, insulin deﬁ-
cient or insulin resistant state and downregulated at fed state
or by insulin [65,66]. The promoter regions of these two genes
have the insulin-responsive elements (IREs) with a T(G/
A)TTT(T/G)(G/T) core sequence, which is quite similar to
FoxO-responsive elements (FREs). In vitro studies, such as re-
porter and gel shift assays, demonstrated that G6pc and Pck1
are target genes of FoxOs. However, the mechanism how Fox-
Os are involved in regulation of their gene expression is quite
complex. Indeed, studies using transgenic mice, which overex-
pressed a constitutively nuclear FoxO1 in liver, enhanced G6pc
FoxOs
Liver
gluconeogenesis
G6Pase
Pgc-1α
TG metabolism
aPoCIII
Pancreatic β-cell
β-cell proliferation
Pdx-1
Protection against
oxidative stress
MafA
NeuroD
Adipose tissues/
adipocytes
p21
Pparγ
Hypothalamus
Acute orexigenic effect
Agrp
Npy
Skeletal muscle
Muscle atorophy
Atrogin-1
MuRF1
Vascular endothelial cells
Regulation of endothelial stability
Ang-2
Sprouty 2
Smooth muscle cells
Myocardin
differentiation
differentiation
differentiation
Pepck
Fig. 3. The summary of metabolic eﬀects of FoxOs in several tissues or cells. In liver, FoxO1 interacts with Pgc-1a, induces G6pcand Pck1 gene
expression, and increases hepatic glucose production. Furthermore, FoxO1 induces aPoCIII gene expression and causes hypertriglyceridemia. In
pancreatic b-cells, FoxO1 inhibits Pdx-1 gene expression and b-cell proliferation. In contrast, FoxO1 inducesMafA and NeuroD gene expression and
confers protection against oxidative stress onto b-cell. In adipocytes, FoxO1 inhibits diﬀerentiation through early induction of p21 Pparc gene
expression. In hypothalamus, acute overexpression of a constitutively nuclear FoxO1 induces Agrp or Npy gene expression and induces orexigenic
eﬀect. In myoblasts, FoxO1 inhibits diﬀerentiation to myotubes. In skeletal muscle, FoxOs induce Atrogin-1 andMuRF1 gene expression and leads to
muscle atrophy. In vascular endothelial cells, FoxOs regulate endothelial stability through induction of Ang-2 and Sprouty 2 genes. In smooth muscle
cells, FoxO4 inhibits diﬀerentiation through inhibitory interaction with myocardin protein.
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proteins binding to IREs accounts for inhibition of basal
Igfbp1 gene expression by insulin and at least in part for inhi-
bition of G6pc gene expression by insulin. However, regulation
of Pck1 by FoxOs remains questionable. Mutagenesis of the
IRE in Pck1 promoter region limited dexamethasone-induced
Pck1 gene expression, consistent with its proposed role as an
accessory factor site. Overexpression of WT FoxO1 also lim-
ited dexamethasone induction, which could result from dis-
placement of another more active factor. Mutagenesis of the
IRE in the promoter region of Pck1 had no eﬀect upon insu-
lin’s inhibition of induction by PKA or by dexamethasone
[68]. Furthermore, in glucogenic kidney epithelial cells, LLC-
PK1-FBPase+ cells that have no expression of FoxO1, overex-
pression of FoxO1 confers insulin inhibition on Dex-cAMP-in-
duced G6pc but not on Pck1 gene expression [69]. However,
the following studies support that FoxO1 may regulate Pck1
gene expression. The decrease in nuclear FoxO1 decreases
Pck1 and G6pc gene expression, decreasing gluconeogenesis
and reducing fasting blood glucose. This has been demon-strated in vivo using adenoviral mediated transfer of a domi-
nant negative FoxO1 into Leprdb/db mice [70].
Furthermore, antisense oligonucleotides of FoxO1 inhibit
Pck1 and G6pc gene expression in primary hepatocytes stimu-
lated with glucagons. Intraperitoneal administration of FoxO1
ASOs decrease Pck1 and/or G6pc gene expression with reduced
hepatic glucose production in liver in lean and diet-induced
obesity mice and improved glucose tolerance in both groups
[71]. These ﬁndings support the previous ﬁnding that FoxO1
increases hepatic gluconeogenesis through involvement of
G6pc and Pck1 gene expression but suggest that FoxO1 is nec-
essary but not suﬃcient for Pck1 gene expression. Indeed,
recently, it has been reported that liver-speciﬁc FoxO1 knock-
out mice showed 40% reduction of glucose levels at birth and
30% reduction in adult mice after 48 h fast. These ﬁndings sup-
port the previous hypothesis that FoxO1 is required for hor-
monal regulation of hepatic glucose production [72].
Microarray study using liver from transgenic mice over-
expressing a constitutively nuclear FoxO1 demonstrated that
FoxO play a role in the regulation of multiple aspects of
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volved in promoting hepatic glucose production was increased
in transgenic mice, which include Pck1 and G6pc. Further-
more, aquaporin 9, which promotes hepatic uptake of glycerol,
was increased. The expression of multiple genes promoting the
catabolism of proteins and amino acid, which also provides
important substrates for gluconeogenesis, was increased.
Therefore, FoxOs may promote hepatic glucose production
by multiple mechanisms.
Coactivator PGC-1a controls gluconeogenic gene expression
by coactivating FoxO1 and HNF-4. During periods of fasting,
once glucagon activates protein kinase-A and followed by
phosphorylation of CREB, Pck1 gene is immediately upregu-
lated. Furthermore, glucagons and glucocorticoid induce
PGC-1a protein level and subsequently up-regulates G6pc
and Pck1 gene expression by coactivating FoxO1 and HNF-
4 [74]. PGC-1a is induced in liver on fasting, and elevated in
several models of diabetes or deﬁciency in insulin actions.
Insulin does not have a direct eﬀect on PGC-1a expression
in cultured hepatocytes or liver. The eﬀect of insulin on
PGC-1a expression in vivo is probably controlled, at least in
part, through counter-regulatory hormones, especially gluca-
gon [75]. In Fao hepatocytes, overexpression of PGC-1a
increased G6pc and Pck1 gene expression. In contrast, a dom-
inant negative FoxO1 (aa1–256), which has no transactivation
domain, inhibits PGC-1a-induced gene expression of G6pc and
Pck1 [76]. These data suggest that PGC-1a requires intact
FoxO1 signaling to activate the gluconeogenic genes and that
PGC-1a and FoxO1 functionally interact.
The apolipoprotein apoC-III plays an important role in TG
metabolism. The apolipoprotein apoC-III functions as an
inhibitor of lipoprotein lipase (LPL), a key enzyme in the
hydrolysis of TG in VLDL and chylomicrons. Elevated plasma
apoC-III are associated with impaired hydrolysis and retarded
clearance of TG-rich particles due to inhibition of hepatic
lipase activity and of apoE-mediated hepatic uptake of TG-
rich remnants, resulting in the accumulation of VLDL-TG
and chylomicrons in plasma and the development of hypertri-
glyceridemia. ApoC-III is mainly produced in liver and its he-
patic production is subject to insulin inhibition. FoxO1 is an
eﬀective mediator of insulin in modulating hepatic apoC-III
expression and in aﬀecting plasma TG metabolism. Transgenic
mice expressing a constitutively nuclear FoxO1 allele exhibited
hypertriglyceridemia. In diabetic NOD and Leprdb/db mice,
hepatic FoxO1 expression was deregulated, as evidenced by
elevated FoxO1 production along with its increased nuclear
localization in liver. These data suggested that FoxO1 deregu-
lation associated with insulin deﬁciency or insulin resistance
played an important role in linking impaired insulin action
to aberrant apoC-III production in the pathophysiology of
diabetic hypertriglyceridemia [77]. In contrast, acute overex-
pression of a constitutively nuclear FoxO1 aﬀects hepatic glu-
cose and lipid metabolism alternatively. Acute overexpression
of FoxO1 mutant using adenoviral system increased hepatic
TG content and reduced plasma insulin, glucose, TG and b-
hydroxybutyrate levels. Increased FoxO1 activity leads to lipid
accumulation by activating TG synthesis through Srebf1 and
inhibiting FFA oxidation through decreased expression of
Ppara78. These two diﬀerent results about eﬀects of overex-
pression of a constitutively nuclear FoxO1 on TG metabolism
might be due to positive feedback loop, interaction withmTOR pathway or unidentiﬁed mechanisms (discussed be-
low).
4.2. Pancreatic b-cell
Several studies using genetically mice models demonstrated
that insulin/IGF-1 signaling in pancreatic b-cell has important
roles in insulin secretion or b-cell proliferation. Knockout mice
of insulin receptor substrate (Irs)-2 develop fasting hyperglyce-
mia, followed by insulin deﬁciency and death from non-ketotic
hyperosmolar coma due to combined insulin resistance in
peripheral tissues and impaired growth of pancreatic b-cells
[79,80]. b-cell speciﬁc insulin receptor (Ir) knockout mice
resulted in progressive glucose intolerance due to impaired
insulin secretion [81]. b-cell-speciﬁc Igf-1r knockout mice
resulted in age-dependent impairment of glucose tolerance,
associated with a decrease of glucose- and arginine-dependent
insulin release [82,83]. Furthermore, a recent study of b-cell
speciﬁc 3-phosphoinositide-dependent protein kinase 1
(Pdk1), which is a serine–threonine kinase that mediates
signaling downstream of PI 3-kinase, knockout mice demon-
strated that Pdk1 is important in maintenance of pancreatic
b-cell mass [84]. However, molecules that are located in down-
stream of Ir/Igf-1 signaling pathway in pancreatic b-cell have
not been known yet for a long time.
Mice models using gain-of-function or loss-of-function
mutant of FoxO1 suggested that FoxO1 had important roles
in b-cell proliferation. Transgenic mice in which a constitu-
tively nuclear FoxO1 (S253A) was expressed both in liver
and pancreatic b-cell (Ttr305) showed early onset of diabetes
due to inhibition of compensatory b-cell growth in response
to peripheral insulin resistance through suppression of the pan-
creatic transcription factor pancreas/duodenum homeobox
gene-1 (Pdx1) expression [67]. This mutant transgene prevents
b-cell replication in another 2 models of b-cell hyperplasia, 1
due to peripheral insulin resistance (Insulin receptor transgenic
knockouts) and 1 due to ectopic local expression of IGF2
(Elastase-IGF2 transgenics) [85]. Haploinsuﬃciency for
FoxO1 reversed b-cell failure in Irs2 knockout mice through
partial restoration of b-cell proliferation and increased expres-
sion of Pdx1 [86]. Haploinsuﬃciency of FoxO1 in b-cell
speciﬁc Pdk1 knockout mice also resulted in a marked increase
in the number of b-cells and resulted in the restoration of
glucose homeostasis [84]. These data suggest that FoxO1 is a
downstream of Irs2/Pdk1 signaling and inhibits compensatory
b-cell proliferation in insulin resistant state.
FoxO1 is also involved in another part of b-cell function
through a diﬀerent mechanism. Chronic exposure to elevated
glucose concentrations causes a deterioration of b-cell function
(glucose toxicity). This glucose toxicity is thought to arise as a
consequence of chronic oxidative stress, when intracellular glu-
cose concentrations exceed the glycolytic capacity of the b-cell.
A recent study suggested a new role of FoxO1 in the protection
against b-cell failure. Exposure of bTC-3 cells to hydrogen per-
oxide, an inducer of superoxide formation, targets FoxO1 to
promyelocytic leukemia-associated protein (Pml)-containing
nuclear subdomains and increases expression of the Ins2 gene
transcription factors NeuroD and MafA in a FoxO1-depen-
dent manner. Acetylation is required to target FoxO1 to nucle-
ar Pml bodies, while deacetylation by the NAD-dependent
deacetylase Sirt1 is required to induce gene expression. Acety-
lation increases FoxO1 stability and targeting FoxO1 to Pml
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radation, where it is deacetylated by Sirt1 to become transcrip-
tionally active. These provide a novel mechanism linking
glucose- and growth factor receptor-activated pathways to
protect b-cells against oxidative damage via FoxO proteins
[41].
4.3. Adipose tissues
Adipose tissue now sits on a central position of in vivo glu-
cose metabolism. Obesity is resulted from positive balance be-
tween energy intake and energy expenditure. Excess amount of
intake is stored as triglycerides in white adipose tissue [87].
Obesity leads to insulin resistance in peripheral tissues due to
altered expression or secretion of adipokines and inﬁltration
of macrophages and subsequently causes type 2 diabetes,
hyperlipidemia, and hypertension and ﬁnally causes athero-
sclerosis [88].
FoxOs are expressed highly in both white and brown adi-
pose tissues [33]. Their expression levels are changed by high
fat diet (Nakae J., unpublished observation). Therefore, it
can be speculated that FoxOs may have some important roles
in these tissues. Insulin or other growth factors are important
for adipocyte diﬀerentiation [89–92]. However, it has not been
known about the mechanism how these growth factors can
regulate adipocyte diﬀerentiation. FoxO1 is expressed little in
preadipocyte cell lines but, during diﬀerentiation, FoxO1
expression level is increased gradually. At the end of clonal
expansion, FoxO1 is localized in nucleus even in the presence
of insulin and serum in medium. After that, FoxO1 is distrib-
uted into cytoplasm. A constitutively nuclear FoxO1 (T24A/
S253D/S316A: ADA) can inhibit adipocyte diﬀerentiation of
3T3-F442A cells due to early induction of p21. Furthermore,
a dominant negative FoxO1, in which a C-terminal transacti-
vation domain is truncated, can restore adipocyte diﬀerentia-
tion of embryonic ﬁbroblasts from insulin receptor knockout
mice [33]. These data suggest that FoxO1 may be a linker be-
tween growth factor-signaling and transcriptional program in
adipocytes during diﬀerentiation and that FoxO1’s activity is
ﬁnely regulated in a diﬀerentiation stage-dependent manner.
Haploinsuﬃciency of FoxO1 in heterozygous insulin recep-
tor knockout mice or high fat-dieted mice improved insulin
sensitivity [67,33]. In these mice, gene expression in adipose tis-
sues was altered compared with high fat-dieted wild type mice.
These ﬁndings suggest several possibilities that (1) FoxO1 in
adipose tissues may have many target genes and up- or
down-regulate their expression in insulin resistant state or (2)
FoxO1 can regulate expression or activity of one or two signal-
ing molecules at transcriptional level or through protein–
protein interaction and can regulate expression of genes in adi-
pose tissues as a whole.
Dowell et al. described an antagonistic relationship between
FoxO1 and Pparc where FoxO1 decreased the formation of a
Pparc/Rxr/DNA complex [93]. Therefore, reducing FoxO1
mRNA expression may lead to improvements in Pparc activ-
ity. Furthermore, it has been reported that FoxO1 can inhibit
PPARc1 and PPARc2 promoter activity through direct inter-
action between FoxO1 and PPARc promoter [94]. Therefore,
FoxO1 may suppress PPARc expression at the transcriptional
level.
Daf-2 mutants or dauer in C. elegans have increased lipid
droplets. Where are these lipids in case of mammalian at insu-lin resistant state? Fat-speciﬁc insulin resistant mice (FIRKO)
showed decreased adiposity [95]. It is speculated that lipid
droplets in C. elegans at dauer stage may be equal to steatosis
or hypertriglyceridemia in mammalian. For elucidation of the
physiological roles of FoxOs in white and brown adipose tis-
sues, we have to wait for studies using genetically modiﬁed
mice, such as adipose tissue-speciﬁc knockout or transgenic
mice of FoxOs.
4.4. Hypothalamus
Recent studies revealed an important role for central insulin
action in glucose metabolism. The administration of insulin
into third ventricular increased the ability of insulin to inhibit
hepatic glucose production in rat [96] whereas central adminis-
tration of insulin receptor antisense caused hepatic insulin
resistance [97]. Brain-speciﬁc insulin receptor knockout mice
showed mild hyperphasia and adiposity in female, diet-sensi-
tive obesity and defects in reproductive function [98]. Further-
more, mice, which had modestly reduced insulin receptor (Insr)
in liver and a near complete ablation of Insr in the arcuate and
paraventricular nuclei of the hypothalamus, had marked
hyperinsulinemia and developed late-onset type 2 diabetes
[99]. These ﬁnding suggest that insulin signaling in CNS is
important for regulation of energy homeostasis. Irs proteins
lie downstream of the Insr and Igf-1r. Female Irs2 knockout
mice showed infertile, hyperphagic, leptin resistant and devel-
oped obesity [100,101]. Mice lacking Irs2 in both pancreatic b-
cell and hypothalamic neuronal population using a rat insulin
2 promoter Cre (RIPCre) recombinase or in all neuron using
Nestin promoter Cre (NesCre) demonstrated hypothalamic
dysfunction [102–104]. These suggest that Irs2 protein has a
critical role in hypothalamic function. Furthermore, a recent
study demonstrated that PI3K is activated by both insulin
and leptin in Pomc neuron, whereas in Agrp neurons, it is acti-
vated by insulin but inhibited by leptin [105]. Thus, the PI3K
pathway in hypothalamus has been implicated in regulation
of food intake and energy homeostasis. However, it has not
been known about the molecular mechanism of a downstream
of Insr/Igf-1r-Irs2-PI3K yet.
In 2006, two groups have reported about roles of FoxO1 in
hypothalamus [106,107]. Both groups showed that FoxO1 is
expressed in hypothalamus, which includes the arcuate
nucleus, ventromedial hypothalamus and dorsomedial hypo-
thalamus. Acute overexpression of a constitutively nuclear
FoxO1, in which three Akt-mediated phosphorylation sites
were substituted to alanine, in rat or mouse arcuate nucleus
by a stereotactic delivery caused increased food intake, body
weight, and leptin and/or insulin resistance. Furthermore,
acute overexpression of a dominant negative FoxO1, in which
a C-terminal transactivation domain was truncated, haploin-
suﬃciency, or knockdown of FoxO1 decreased food intake
and increased leptin sensitivity. A constitutively nuclear
FoxO1 increased orexigenic neuropeptides, Agouti-related pro-
tein (Agrp) and neuropeptide Y (Npy), gene expression, and
inhibited pro-opiomelanocortin (Pomc) gene expression
through competition with Stat3 on Pomc promoter region.
These novel ﬁndings suggest that FoxO1 in arcuate nucleus
may activate feeding behavior.
However, there are still points, which should be clariﬁed.
The ﬁrst one is which neurons in hypothalamus, especially
in the arcuate nucleus, are truly important for FoxO1’s action
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tic delivery of adenovirus encoding a constitutively nuclear
FoxO1, it was not accomplished about overexpression in par-
ticular neuron-speciﬁc manner. The second point is ‘‘how
about the long term eﬀects of overexpression of FoxO1 in
hypothalamus on food intake and glucose metabolism’’.
The last point is whether signaling molecules of upstream
of FoxO1, such as Akt or Pdk1, are expressed and functioned
truly in hypothalamic speciﬁc neurons, such as Agrp/Npy or
Pomc/Cart neurons, or whether these molecules are co-ex-
pressed with FoxO1 in these neurons. For the purpose of
these analyses, studies using neuron-speciﬁc FoxOs knockout
mice or neuron-speciﬁc FoxO transgenic mice should be
waited.
4.5. Skeletal muscle
FoxOs are expressed in skeletal muscle and their expression
levels are changed in response to energy metabolism. Expres-
sion levels of FoxO1 and FoxO3a were increased in skeletal
muscle by starvation and glucocorticoid treatment [108]. Skel-
etal muscle has an important role for the regulation of glucose
metabolism. These ﬁndings facilitate us to speculate that Fox-
Os may have some physiological roles in skeletal muscle.
It has been recognized that IGF-1 is involved in myoblast
diﬀerentiation through PI3K/Akt [109]. Inactivation of IGF
signaling by targeted mutagenesis of IGF1 receptor leads to
muscle hypoplasia [110], whereas overexpression of IGF1
results in enlarged myoﬁbers [111]. However, downstream
targets of PI3K/Akt have not been known for a long time. Re-
cent ﬁndings demonstrated that FoxOs have important roles in
myoblast diﬀerentiation [112]. In C2C12 cells, FoxOs protein
expression is decreased during diﬀerentiation and phosphory-
lated in myotubes. Overexpression of a constitutively nuclear
FoxO1 in C2C12 cells inhibits diﬀerentiation from myoblasts
to myotubes. In contrast, a dominant negative FoxO1 partially
rescues inhibition of C2C12 diﬀerentiation mediated by wort-
mannin. Furthermore, knockdown of endogenous FoxOs
resulted in increased myosin expression. In P19 teratocarci-
noma cells, a dominant negative FoxO1 enhances myoblast
diﬀerentiation and a constitutively nuclear FoxO1 inhibits it.
These ﬁndings suggest that FoxOs are implicated in IGF-
dependent myoblast diﬀerentiation.
On the other hand, mass and ﬁber size in adult skeletal mus-
cle is regulated in response to changes in workload, activity, or
pathological conditions, which include cancer, diabetes melli-
tus, sepsis, and Cushing’s syndrome [113]. The control of mus-
cle mass is regulated by a dynamic balance between anabolic
and catabolic processes. Hypertrophy of muscle is associated
with increased protein synthesis, while atrophy enhances pro-
tein degradation. Muscle atrophy is characterized by increased
protein degradation processes, especially the ATP-dependent
ubiquitin-proteasome proteolytic pathway, and increased tran-
scriptional adaptation that constitute an atrophy program.
Interestingly, decreased activity of IGF-1/PI3K/Akt signaling
pathway can lead to muscle atrophy [114]. It has been shown
that two genes are induced in muscle atrophy [115]. These
genes are MAFbx (muscle atrophy F box, Atrogin-1) and
MuRF1 (muscle RING ﬁnger 1), which function to conjugate
ubiquitin to protein substrates. Indeed, MAFbx or MuRF1
knockout mice showed sparing of muscle mass following
denervation. In C2C12 cells, the IGF/PI3K/Akt pathway inhib-its atrogin-1 and MuRF1 gene expression through inactivation
of FoxOs and inhibition of FoxOs reduces the induction
of atrogin-1 gene expression induced by glucocorticoids
[116,117]. Furthermore, activation of FoxOs causes dramatic
atrophy of myotubes and mature muscle ﬁbers. Indeed, during
atrophy, FoxO1 and FoxO3a gene expression levels are in-
creased and reduced Akt activity causes dephosphorylation
of FoxOs and activates them. These data suggest that IGF-1/
PI3K/Akt signaling pathway can not only induce muscle
hypertrophy through activation of protein synthesis but also
inhibit the activation of muscle atrophy pathway through inhi-
bition of FoxOs activity. A skeletal muscle-speciﬁc FoxO1
transgenic mice using human skeletal muscle a-actin promoter
showed reduced body weight due to a decreased lean body
mass [118]. The skeletal muscles from transgenic mice were
smaller in size and dry mass, as well as paler in color than
those of control mice. Furthermore, the transgenic mice
showed poor glycemic control and low capacity for physical
exercise. These phenotypes of the transgenic mice are consis-
tent with the ﬁndings of cell lines described above and support
the previous ﬁndings that FoxO1 negatively regulates skeletal
muscle mass.
4.6. Vascular endothelial cells
Insulin receptors (IRs) have been demonstrated on endothe-
lial cells of both large and small blood vessels [119]. The ﬁnd-
ings that vascular endothelial cell-speciﬁc IR knockout mice
(VENIRKO) on a low-salt diet showed signiﬁcant insulin resis-
tance suggest that insulin signaling in endothelial cells partici-
pates in the mechanism that correct whole-body insulin
sensitivity and vascular function [120].
The previous ﬁnding that FoxO1-null mice showed defects in
vasculogenesis [60,61] and also the recent report that inducible,
wide spread somatic FoxO deleted adult mice,Mx-Cre+;
FoxO1/3/4L/L, caused systemic occurrence of haemangioma
in limited tissues, which include uterus, liver, and muscle
[63]. These data suggest a physiological role of FoxOs in vas-
cular system and that FoxO1 is the most physiologically
important factor of endothelial stability. Sprouty 2 was identi-
ﬁed as a target molecule of FoxOs. Because Sprouty 2 is an
inhibitor of growth factor receptor tyrosine kinase signaling,
FoxOs might regulate EC response to extracellular angiogenic
stimuli [63].
It has been reported that angiopoietin (Ang)-1, a regulator
of vascular maturation and stability as well as an endothelial
cell survival factor, inhibits FoxO1 activity by phosphoryla-
tion through Tie2/Akt pathway [121]. FoxO1 modulates
expression of genes, which are associated with blood vessel
destabilization and remodeling and apoptosis. FoxO1 induces
Ang-2 gene expression. Ang-2 is an Ang-1 antagonist and
binds but does not activate Tie2. Ang-2 is associated with
blood vessel destabilization and remodeling. The positive feed-
back that FoxO1 activates FoxO1 itself through antagonizing
Ang-1/Akt pathway through induction of Ang-2 may explain
that FoxO1 can change expression of various genes that are
involved in vessel destabilization, matrix remodeling in vascu-
lature, endothelial cell migration, or tube formation. The
alteration of gene expression in blood vessel suggests that
FoxO1 activation is likely to be coupled to changes in the
interaction between endothelial cells and the surrounding sup-
port cells and matrix.
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Abnormal proliferation and migration of smooth muscle
cells (SMCs) contribute to the pathogenesis of atherosclerosis,
restenosis following angioplasty, hypertension, and leiomyo-
sarcoma [122]. SMCs do not diﬀerentiate terminally and can
transit between a quiescent, contractile phenotype and a prolif-
erative synthetic phenotype in response to physiological and
pathological stimuli [123]. In response to vascular injury, dif-
ferentiated SMCs proliferate and dediﬀerentiate. At the same
time, SMCs express contractile proteins required for normal
cardiovascular homeostasis. Expression of genes encoding
smooth muscle-speciﬁc contractile proteins and extracellular
matrix proteins is characteristic for vascular SMC diﬀerentia-
tion and phenotypic modulation.
A CarG box (CC(A/T)6GG), which is the binding site in
the promoter region for serum response factor (SRF), a
MADS (MCM1, Agamous, Deﬁciens, SRF) box transcription
factor, is important for expression of SMC contractile genes
[124]. Myocardin is a potent coactivator of SRF that can acti-
vate the program of SM diﬀerentiation in transfected ﬁbro-
blasts. Myocardin is suﬃcient and necessary for activation
of SM contractile protein genes [125]. Activation of the
PI3K/Akt signaling pathway promotes SMC diﬀerentiation
and FoxO4 is the most abundant family member in myo-
cyte-containing tissues. Liu, et al. demonstrated that a consti-Fasting
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Fig. 4. Positive feedback loop of FoxOs on insulin signaling. Fasting, starvati
FoxOs and nuclear import. Nuclear FoxOs induce expression of their target
(IRS2) and 4EBP1. Enhanced expression of IR and IRS2 phosphorylate and a
Increased expression of 4EBP1 causes growth retardation and sparing of nututively nuclear FoxO4 inhibits SMC diﬀerentiation through
a mechanism independent of DNA binding, whereas knock-
down of endogenous FoxO4 in SMCs increased expression
of SM contractile genes. They also showed that FoxO4 forms
a ternary complex with myocardin and SRF and inhibit the
transcriptional and myogenic activities of myocardin [126].
Furthermore, it has been reported that FoxO4 is also a tran-
scriptional activator of myocardin [127]. Therefore, FoxO4
might ﬁne-tune the potent transcriptional activity of myocar-
din and regulate the diﬀerentiation of SMCs. Indeed, the ﬁnd-
ing that FoxO4-null mice display impaired neointima
formation after carotid artery ligation, which is a potent stim-
ulus for phenotypic modulation of SMCs, suggests that
FoxO4 is required for vascular remodeling following injury
to the vessel wall.5. FoxOs can regulate activity of insulin signaling molecules
FoxOs cause insulin resistance through induction of expres-
sion of several genes, which are involved in metabolism. How-
ever, recent ﬁndings suggest that FoxOs can alleviate insulin
resistance through positive feedback loop on insulin signaling
(Fig. 4) and also that FoxOs can interact with mTOR pathway
by several ways.IR
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on, insulin deﬁciency, or insulin resistance causes dephosphorylation of
genes, which include insulin receptor (IR), insulin receptor substrate 2
ctivate Akt, leading to phosphorylate and export FoxOs nucleus again.
trient storage.
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FoxOs has inhibitory eﬀects on insulin actions, such as in-
creased glucose production in liver, inhibition of compensa-
tory pancreatic b-cell proliferation in response to peripheral
insulin resistant state, or increased food intake through regula-
tion of gene expression of hypothalamic neuropeptides. How-
ever, FoxOs provide rapid changes on insulin signaling in
response to a nutritional status or hormonal environment be-
tween fasting and fed state.
In Drosophila, Drosophila FoxO (dfoxo) activates transcrip-
tion of the insulin receptor (dir) and translational repressor
d4ebp expression [128]. In the nutrition-limited state, dfoxo en-
hances dir expression to prime for changes in nutrient avail-
ability and 4ebp expression to inhibit growth in order to
spare nutrient storage. FoxO1 also increases one of insulin
receptor substrate (Irs), Irs2, at transcriptional level [129].
Irs2 has several important roles in metabolism in a tissue-
speciﬁc manner. The induction of Irs2 by activated FoxO1
in insulin resistant state may improve insulin sensitivity. Fur-
thermore, recent reports demonstrated that a constitutively
nuclear FoxO1 (ADA) increased Akt phosphorylation in
Trb3 (Tribbles homolog 3)-dependent or -independent manner
[78,130].
Many signaling pathways are converged on FoxO1 and
FoxO1 not only induces or represses expression of target
genes, which are involved in metabolism in each insulin-
responsive tissue, but also performs transcriptional control
on signaling molecules. These novel ﬁndings make FoxO1 a
central metabolic regulator in glucose and lipid metabolism.5.2. Interaction between FoxOs and mTOR pathway
It has been reported that ribosomal p70 S6 kinase (p70S6K)
enhances IRS-1 serine phosphorylation, which lead to de-
creased Akt phosphorylation and causes insulin resistance.
Therefore, mTOR/p70S6K signaling pathway can modulate
IRS-1/PI3k/Akt/FoxO pathway. The activity of mTOR/
p70S6K pathway is regulated by TSC2 (also known as tuberin).
TSC1 and TSC2 physically associate in vivo and form a hetero-
dimeric complex. Akt-phosphorylation of TSC2 leads to the
functional inactivation of the TSC1–TSC2 complex and results
in mTOR activation leading to phosphorylation of two main
mTOR substrates, p70S6K and eukaryotic initiation factor
4E-binding protein (4E-BP1), and elevated mRNA translation.
In Drosophila, one of hypomorphic mutation of dTOR, a
dTOR P-element insertion (dTOR7/P mutant), showed lipid
breakdown due to increased lipase activity and increased con-
version of lipids to ketone bodies, decreased blood glucose lev-
els due to increased production of insulin-like peptide (DILP2)
in insulin producing cells (IPCs). In contrast, systemic expres-
sion of a constitutively nuclear dFOXO (dFOXO-TM) results
in increased lipid levels, decreased DILP2 mRNA levels, and
high glucose levels. Interestingly, reduced dTOR activity in
dTOR7/P can block dFOXO-TM-mediated relevant metabolic
targets to reverse the increased glucose and lipid phenotype.
Therefore, the dTOR mutant phenotype can block activated
dFOXO-TM-mediated insulin resistance phenotypes although
the mechanism by which reduced dTOR activity inhibits activ-
ity of a constitutively nuclear dFOXO (dFOXO-TM) has not
been clear yet [131].
Recently, Melted, which is associated with both dTsc1 and
dFOXO in Drosophilla, was identiﬁed as an activator ofdTOR signaling and an inhibitor of dFOXO. The melted gene
encodes a C-terminal Pleckstrin Homology (PH) domain pro-
tein and can recruit the Tsc1-Tsc2complex to the plasma mem-
brane and modulate its output via dTOR pathway and can
also recruit dFOXO to the membrane in an insulin-responsive
manner and thereby inﬂuence expression of dFOXO’s target
genes. The predicted Melted protein is conserved beyond dif-
ferent species, C. elegans, mice, and human. The ﬁndings that
melted mutant demonstrated 10% reduced body size and 60%
of triglyceride content of wild type ﬂy suggest that Melted
activity is required in adipose tissue. Melted acts by regulating
FOXO activity to control expression of genes important in fat
metabolism [132]. From studies on Melted in Drosophila, it can
be speculated that mammalian homolog of Melted may have
some important roles in metabolism aﬀecting both mTOR
and FoxOs activity. We also identiﬁed TSC2 as a FoxO1-bind-
ing protein by yeast two hybrid screening using murine islets
cDNA. Physical association between TSC2 and FoxO1 inhib-
its TSC2 function for inhibition to mTOR and leads to en-
hance p70S6K phosphorylation. The ﬁnding that knockdown
of endogenous FOXO1 in HUVEC inhibits p70S6K phos-
phorylation suggests that FOXO1 has a physiological role in
regulation of activity of mTORC1 signaling [133].6. Conclusion
CR or starvation lowers blood glucose and insulin levels, de-
creases insulin actions and results in nuclear accumulation of
FoxOs. FoxOs can accelerate glucose production, reduced
insulin secretion, decreased fat and muscle masses and leads
to spare energy in vivo. FoxOs should be necessary for survival
in lower organisms evolutionally and be conserved beyond spe-
cies. However, in human, excessive calorie intake causes obes-
ity and insulin resistance. At these circumstances, FoxOs
should be active even not in CR state. Deregulated and unnec-
essary FoxOs’ activity may cause and accelerate insulin resis-
tance and ﬁnally lead to type 2 diabetes and hyperlipidemia.
The inhibition of this viscous cycle by inactivation of FoxOs
may shed light on the treatment of type 2 diabetes and also
the metabolic syndrome.
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